Brief: Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026
06/01/2026 14:00
Jan 6 (Reuters) - Denali Therapeutics Inc DNLI.O: DENALI THERAPEUTICS ANNOUNCES KEY ANTICIPATED MILESTONES AND PRIORITIES FOR 2026 INCLUDING COMMERCIAL LAUNCH OF TIVIDENOFUSP ALFA FOR HUNTER SYNDROME DENALI THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD ON DNL952, PHASE 1 STUDY TO PROCEED DENALI THERAPEUTICS INC - PREPARES FOR FDA APPROVAL AND LAUNCH OF TIVIDENOFUSP ALFA Source text: ID:nGNX5hmFVt Further company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers